Frontier Biotechnologies 관리

관리 기준 확인 3/4

Frontier Biotechnologies CEO는 C. J. Wang, Jan2013 에 임명되었습니다 의 임기는 11.83 년입니다. 는 CN¥ 156.47M 가치에 해당하는 회사 주식의 5.62% 직접 소유합니다. 156.47M. 경영진과 이사회의 평균 재임 기간은 각각 10.3 년과 6.5 년입니다.

주요 정보

C. J. Wang

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	11.8yrs
CEO 소유권	5.6%
경영진 평균 재임 기간	10.3yrs
이사회 평균 재임 기간	6.5yrs

최근 관리 업데이트

Recent updates

CEO

C. J. Wang (66 yo)

11.8yrs

테뉴어

CN¥2,228,000

보상

Dr. Changjin Wang, also known as C. J., Ph D., serves as Chief Executive Officer and Director at Frontier Biotechnologies Inc. since January 2013. Dr. Wang served as Vice President of Business Development...

리더십 팀

이름	위치	테뉴어	보상	소유권
Qi Shao	Senior VP & CFO	8.8yrs	CN¥1.37m	데이터 없음
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	no data	CN¥593.80k	데이터 없음
Hangzhou Lv	Senior Vice President of Marketing & Sales	no data	CN¥1.22m	데이터 없음
Qianya Gao	Deputy GM & Secretary of the Board of Directors	3.9yrs	CN¥962.00k	데이터 없음
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Xiao Zheng	Chief Operating Officer	3.7yrs	CN¥3.47m	데이터 없음
Michael Hu	C.M.O.	no data	데이터 없음	데이터 없음

10.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 688221 의 관리팀은 노련하고 경험 (평균 재직 기간 10.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	5.8yrs	CN¥593.80k	데이터 없음
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Chi Kit Ng	Independent Director	5.8yrs	CN¥150.00k	데이터 없음
Yuantao Cao	Supervisor	6.5yrs	데이터 없음	데이터 없음
Guangji Wang	Independent Director	2.5yrs	CN¥130.20k	데이터 없음
Kai Chen	Independent Director	5.8yrs	CN¥90.70k	데이터 없음
Zhi Zhong Jiang	Chairman of the Supervisory Board & Purchasing Director	8.8yrs	CN¥380.60k	데이터 없음

6.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: 688221 의 이사회는 경험(평균 재직 기간 6.5 년)으로 간주됩니다.

Frontier Biotechnologies 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령